Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain
caused by the JC virus (JCV). PML usually occurs via reactivation of JCV when an immune …

Natalizumab is a new treatment option for patients with active relapsing-remitting multiple
sclerosis. In phase III studies, natalizumab was highly effective and well tolerated; however …

OBJECTIVE: Chronic immunosuppressive therapy may be complicated by infections
indicating a more or less profound immune defect. However, immune monitoring to estimate …

Rituximab Therapy for Membranous Nephropathy: A Systematic R... : Clinical Journal of the
American Society of Nephrology Rituximab Therapy for Membranous Nephropathy: A …

Progressive multifocal leukoencephalopathy (PML) is a rare and devastating neurological
disease with areas of demyelination in the central nervous system classically associated …

The implementation of a variety of immunosuppressive therapies has made drug-associated
progressive multifocal leukoencephalopathy (PML) an increasingly prevalent clinical entity …

Objective To determine risk factors for progressive multifocal leukoencephalopathy (PML) in
systemic lupus erythematosus (SLE) patients, and understand how underlying disease or …

Background: Immunosuppressive treatment of rheumatic diseases may be associated with
several opportunistic infections of the brain. The differentiation between primary central …

Central nervous system (CNS) involvement in systemic lupus erythematosus (SLE) can
produce a broad range of disease-specific neuropsychiatric manifestations that must be …

Background: Patients receiving immunosuppressive therapy with corticosteroids and
cytotoxic agents may develop opportunistic infections such as Pneumocystis carinii …